Physician profile
William H Fleming
NPI 1255384574
$27,273.68
in general payments reported to CMS, 2019-2025
61 companies · $35.07 in 2025
The $35.07 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,867 · 2020: $2,890 · 2021: $6,139 · 2022: $11K · 2023: $3,609 · 2024: $945 · 2025: $35.07.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,235 · Consulting Fee: $1,338 · Education: $16.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,234.75 |
| Consulting Fee | $1,338.00 |
| Education | $16.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $11,962.67 | 2019-2023 | Tysabri, Vumerity |
| Argenx US, INC. | $1,343.43 | 2022-2023 | Vyvgart, Vyvgart Hytrulo |
| Supernus Pharmaceuticals, INC. | $1,132.19 | 2019-2024 | Qelbree, Qelbree |
| Novartis Pharmaceuticals Corporation | $1,014.85 | 2019-2021 | |
| Abbvie INC. | $865.50 | 2020-2023 | |
| Alexion Pharmaceuticals, INC. | $800.70 | 2019-2024 | Ultomiris, Soliris |
| Ucb, INC. | $766.84 | 2019-2024 | Nayzilam, Briviact, Rystiggo |
| Genzyme Corporation | $721.41 | 2019-2023 | |
| Teva Pharmaceuticals USA, INC. | $624.50 | 2019-2024 | Austedo Xr, Austedo |
| Acadia Pharmaceuticals INC | $601.69 | 2019-2023 | Nuplazid |
| Genentech USA, INC. | $532.14 | 2019-2023 | Enspryng, Ocrevus |
| Eisai INC. | $513.51 | 2019-2024 | |
| Sk Life Science, INC. | $466.46 | 2020-2024 | |
| Adamas Pharmaceuticals, INC. | $388.43 | 2019-2021 | |
| Abbott Laboratories | $378.59 | 2019-2024 | Infinity |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Fleming listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.